Gerald Belle - Interpace Diagnostics Insider

Interpace Diagnostics Group Inc -- Exotistan Stock  

USD 0.53  0.06  10.17%

Independent Chairman of the Board

Mr. Gerald P. Belle is Independent Chairman of the Board of PDI Inc. He joined us as a director in April 2008 and was the Chairman of the Board since June 2010. From 2004 until his retirement in November 2007 Mr. Belle served as Executive Chairman of Merial Ltd. a global animal health company that was a joint venture between SanofiAventis and Merck Co. Prior to that Mr. Belle served as President and Chief Executive Officer North America Pharmaceuticals for Aventis Inc. He retired after 35 years of service at Aventis and its predecessor companies. Mr. Belle formerly was chairman of the board of directors of Myrexis Inc. a biopharmaceutical company from February 2009 until February 2013. He was a member of the board of directors of Myriad Genetics Inc. a genetics diagnostic company from November 2007 through November 2009. Mr. Belle earned a B.S.B.A. in Marketing from Xavier University in 1968 and an M.B.A. from Northwestern University in 1969. Mr. Belle has held senior leadership positions in companies in the pharmaceutical and life sciences industries. In addition his specific experiences qualifications and skills in the functions of sales sales management and general management in the United States operations in the United States Asia Europe and Canada and financial operations and administration led the Board to conclude that Mr. Belle should serve as a director of the Company.
Age: 68  Chairman Since 2010  MBA    
Belle earned a B.S.B.A. in Marketing from Xavier University in 1968 and an M.B.A. from Northwestern University in 1969.

Management Efficiency

The company has return on total asset (ROA) of (15.11) % which means that it has lost $15.11 on every $100 spent on asset. This is way below average.
The company currently holds 27.91 M in liabilities with Debt to Equity (D/E) ratio of 4.76 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Interpace Diagnostics Group Inc has Current Ratio of 1.0 suggesting that it may have difficulties to pay its financial obligations when they are due.

Similar Executives

Found 1 records


Ahmad AdlaniBank Tabungan Negara

Entity Summary

PDI, Inc. offer outsourced commercial services to pharmaceutical, biotechnology, diagnostics, and healthcare companies in the United States. Interpace Diagnostics Group Inc (PDII) is traded on Commodity Exchange in Exotistan. It is located in PDI, Inc.Parsippany, NJ and employs 775 people.

Did you try this?

Run Global Markets Map Now

Global Markets Map

Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Hide  View All  NextLaunch Global Markets Map
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Interpace Diagnostics Group Inc to your portfolio

Top Management

Interpace Diagnostics Leadership Team
Stephen Sullivan, Director, MBA
Graham Miao, President
Kapila Ratnam, Director
Nancy Lurker, CEO
Jennifer Leonard, SVP
Veronica Lubatkin, Director
Gerald Melillo, Executive
Heiner Dreismann, Director
Jack Stover, Director
Frank Arena, SVP
Asher Dewhurst, Executive
John Federspiel, Director, MBA
Gerald Belle, Chairman, MBA

Stock Performance

Interpace Diagnostics Performance Indicators